Weiqing Han

机构：Nanchang University, Second Affiliated Hospital of Nanchang University

发表论文 15 篇 · 总被引 126 次 · h-index 6

代表论文

• A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. (2019 · Journal of Clinical Oncology · 被引 39)
• RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. (2022 · Journal of Clinical Oncology · 被引 33)
• Abstract CT175: Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study (2023 · Cancer Research · 被引 13)
• A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma (2024 · European Journal of Cancer · 被引 10)
• Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial (2023 · Chinese Medical Journal · 被引 9)
• MRG002-006: A multicenter phase II clinical trial of MRG002-ADC for unresectable locally advanced or metastatic urothelial cancer. (2022 · Journal of Clinical Oncology · 被引 7)